Sign in

You're signed outSign in or to get full access.

Qize Ding

Research Analyst at Redburn Atlantic

Qize Ding is an Analyst specializing in biotechnology and pharmaceutical equities at Redburn Atlantic, where he covers major companies such as Legend Biotech and Genmab. Notably, he initiated coverage of Legend Biotech with a Buy rating and projected significant upside, with documented calls returning as high as 181.97% and earning a 92.47% upside rating on Genmab from TipRanks, reflecting strong performance in investment recommendations. Ding joined Redburn Atlantic in 2024 and is recognized for data-driven ratings and successful stock selection in the healthcare sector, with earlier career details and professional licenses not publicly disclosed. His analytical expertise is evidenced by high-accuracy calls and a focus on growth-oriented biopharma stocks.

Qize Ding's questions to GENMAB (GMAB) leadership

Question · Q4 2025

Qize Ding noted petosemtamab is in Phase 2 for combination with pembrolizumab in first-line non-small cell lung cancer (NSCLC) and asked if this was a new trial started in Q4 2025, requesting high-level thoughts and expectations behind the study.

Answer

Chief Development Officer Judith Klimovsky confirmed that EGFR is a relevant target for lung cancer. She explained that the study was planned as a signal-seeking trial in indications where Cetuximab showed maximum benefit, and in combination with pembrolizumab due to the known synergy between petosemtamab and pembrolizumab. Klimovsky stated it is a signal-seeking study and updates will be provided when data becomes available.

Ask follow-up questions

Fintool

Fintool can predict GENMAB logo GMAB's earnings beat/miss a week before the call

Question · Q4 2025

Qize Ding sought clarification on a new Phase II trial for petosemtamab in combination with pembrolizumab in first-line non-small cell lung cancer (NSCLC), reportedly started in Q4 2025, and asked for high-level thoughts and expectations behind this study.

Answer

CEO Jan van de Winkel and Chief Development Officer Judith Klimovsky addressed the question. Klimovsky confirmed the study, noting that EGFR is a good target for lung cancer. The Phase II trial is a signal-seeking study, planned in indications where Cetuximab showed maximum benefit, and in combination with pembro due to observed synergy. Genmab will provide updates when data is available.

Ask follow-up questions

Fintool

Fintool can write a report on GENMAB logo GMAB's next earnings in your company's style and formatting

Question · Q2 2025

Qize Ding from Redburn Atlantic asked for more detail on the planned RINA S trial in non-small cell lung cancer, specifically the line of therapy and whether it would be tested as a monotherapy or in combination.

Answer

Citing the competitive landscape, Chief Medical Officer Tahamtan Ahmadi declined to provide specific details but confirmed the study is designed to explore RINA S as both a monotherapy and in combination therapy. He suggested the company's past development strategies offer a clue to the approach.

Ask follow-up questions

Fintool

Fintool can auto-update your Excel models when GENMAB logo GMAB reports

Question · Q2 2025

Qize Ding from Redburn Atlantic asked for follow-up details on the RINA S Phase II trial in non-small cell lung cancer, specifically whether it would target first or second-line settings and test RINA S as a monotherapy or in combination.

Answer

Tahamtan Ahmadi, EVP & Chief Medical Officer, responded cautiously due to the competitive landscape. He confirmed the study is designed with the optionality to test RINA S both as a monotherapy and in combination, suggesting that Genmab's established development philosophy provides a guide to the likely strategic approach.

Ask follow-up questions

Fintool

Fintool can alert you when GENMAB logo GMAB beats or misses